MWN-109 in Diabetes Mellitus: NCT07787728 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Completed
Recruitment status
40
Planned enrollment
2025-12-16
Primary-completion proxy
Executive view
NCT07787728 evaluates MWN-109 in Diabetes Mellitus. The disclosed sponsor is Shanghai Minwei Biotechnology Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Incidence of adverse events (AEs) and serious adverse events (SAEs), assessed over From Day 1 to Day 113.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07787728 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Diabetes Mellitus landscape. Drug & Asset MCP drug_fetch was queried for MWN-109, while Company & Deal Intelligence MCP organization_fetch was queried for Shanghai Minwei Biotechnology Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07787728 | MWN-109 | Phase 1 / Completed | Shanghai Minwei Biotechnology Co., Ltd. | China | Incidence of adverse events (AEs) and serious adverse events (SAEs) From Day 1 to Day 113 | 2025-12-16 |
| NCT07803705 | Mazdutide | Not Applicable / Not yet recruiting | Shanghai Tongji Hospital | China | Percentage change in Intrapancreatic Fat Deposition (IPFD) from baseline From baseline to Week 48 | 2028-06-30 |
| NCT07803744 | Acetaminophen | Phase 1 / Not yet recruiting | Eli Lilly & Co. | United States | Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen Predose on Day 1 through 36 hours post dose | 2026-12-01 |
| NCT07804797 | MWN-109 | Phase 2 / Active, not recruiting | Shanghai Minwei Biotechnology Co., Ltd | China | Percentage change in body weight compared to baseline after 24 weeks of drug administration Baseline, Week 24 | 2026-09-01 |
| NCT07804810 | MWN105 | Phase 2 / Completed | Shanghai Minwei Biotechnology Co., Ltd | China | Percentage Change from Baseline in Body Weight at Week 24. Baseline, Week 24 | 2026-03-21 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07787728 is a Phase 1, completed study with 40 planned participants. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment.
The primary endpoint is “Incidence of adverse events (AEs) and serious adverse events (SAEs)” over “From Day 1 to Day 113.” The retrieved endpoint description is: Safety and tolerability assessed by the incidence of AEs and SAEs..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 40 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
3 recent result records were selected as contextual evidence for Diabetes Mellitus. These records do not establish direct evidence for NCT07787728 unless the registration number matches.
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
Phase 4; n=79; Change in Stress Myocardial Perfusion Reserve on Cardiac MRI(Least Squares Mean): P-Value = 0.97; Change in Stress Myocardial Perfusion Reserve on Cardiac MRI(Least Squares Mean) = 0.154 ratio of mL/min/g per mL/min/g (95% Confidence Interval, -0.122 to 0.430) Source: https://clinicaltrials.gov/ct2/show/results/NCT04519164
Lifestyle Intervention Plus Metformin to Treat Frailty in Older Veterans With Obesity
Phase 3; n=114; Change in the Modified Physical Performance Test (PPT)(Mean) = 1.2 Score on a Scale (Standard Error, 0.4); Change in the Modified Physical Performance Test (PPT)(Mean): Mean Difference (Net) = 2.5(95% CI, 1.2 - 3.8), P-Value = 0.0002; Mean Difference (Net) = 0.1(95% CI, -1.2 to 1.4), P-Value = 0.92 Source: https://clinicaltrials.gov/ct2/show/results/NCT04221750
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome (PWS)
Phase 2; n=19; Incidence of Treatment Emergent Adverse Events (TEAE) = 8 Participants ; Incidence of Treatment Emergent Adverse Events (TEAE) = 5 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05153434
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
MWN-109 is indexed as Synthetic peptide with GCGR x GIPR x GLP-1R biology and a global stage of Phase 3. The asset profile lists Shanghai Minwei Biotechnology Co., Ltd as an originator or developer.
Shanghai Minwei Biotechnology Co., Ltd. is indexed in China with the website http://www.minweibiotech.cn. Operates as a biotechnology company that provides clinical trails, drug development and technology services The record lists an unreported number of development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether MWN-109 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07787728
Protocol source: https://clinicaltrials.gov/study/NCT07787728
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
MWN-109 in Diabetes Mellitus is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence of adverse events (AEs) and serious adverse events (SAEs) and 2025-12-16 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
